Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies

mAbs

Volumn 4, Issue 6, 2012, Pages 653-663

  Klein, Christian ^a   Sustmann, Claudio ^b   Thomas, Markus ^b   Stubenrauch, Kay ^b   Croasdale, Rebecca ^b   Schanzer, Jürgen ^b   Brinkmann, Ulrich ^b   Kettenberger, Hubert ^b   Regula, Jörg T ^b   Schaefer, Wolfgang ^b  

^a Roche Glycart   (Switzerland)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Antibody; Bispecific; CrossMab; DAF; Heavy chain; Heterodimerization; Knobs into holes; Light chain

Indexed keywords

ANGIOPOIETIN RECEPTOR ANTIBODY; ANTIBODY CONJUGATE; BEVACIZUMAB; BISPECIFIC ANTIBODY; CATUMAXOMAB; CETUXIMAB; CVX 241; DUAL ACTING ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; HETERODIMER; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; METMAB; RECEPTOR ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; DIMERIZATION; HETERODIMERIZATION; HOMODIMERIZATION; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; INFUSION RELATED REACTION; MALIGNANT ASCITES; MUTATION; NONHUMAN; PROTEIN DOMAIN; REVIEW;

ANTIBODY; BISPECIFIC; CROSSMAB; DAF; HEAVY CHAIN; HETERODIMERIZATION; KNOBS-INTO-HOLES; LIGHT CHAIN;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; SINGLE-CHAIN ANTIBODIES;

EID: 84869783247     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.21379     Document Type: Review

References (67)

1. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747
2. Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011; 317:1261-9; PMID:21371474; http://dx.doi.org/10.1016/j.yexcr.2011.02.013
3. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
4. Fischer N, Léger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007; 74:3-14; PMID:17496428; http://dx.doi.org/10.1159/000101046
5. Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC. Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci U S A 2012; 109:875-80; PMID:22219363; http://dx.doi.org/10.1073/pnas.1120059109
6. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med 2011; 3:84ra43; PMID:21613622; http://dx.doi.org/10.1126/ scitranslmed.3002254
7. Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
8. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010; 2:129-36; PMID:20190561; http://dx.doi.org/10.4161/ mabs.2.2.11221
9. Holmes D. Buy buy bispecific antibodies. Nat Rev Drug Discov 2011; 10:798-800; PMID:22037028; http://dx.doi.org/10.1038/nrd3581
10. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11- 0820
11. Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A 2010; 107:22611-6; PMID:21149738; http://dx.doi.org/10.1073/pnas.1016478108
12. Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; http://dx.doi.org/10.1093/protein/gzq028
13. Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 2008; 11:675-87; PMID:18729019
14. Fitzgerald J, Lugovskoy A. Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs 2011; 3:299-309; PMID:21393992; http://dx.doi.org/10.4161/mabs.3.3.15299
15. Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci U S A 2011; 108:8194-9; PMID:21536919; http://dx.doi.org/10.1073/pnas. 1018565108
16. Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother 2011; 55:2369-78; PMID:21300827; http://dx.doi.org/10.1128/ AAC.00215-10
17. Digiammarino EL, Harlan JE, Walter KA, Ladror US, Edalji RP, Hutchins CW, et al. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. MAbs 2011; 3:487-94; PMID:21814039; http://dx.doi.org/10.4161/mabs.3.5.16326
18. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
19. Herrmann T, Grosse-Hovest L, Otz T, Krammer PH, Rammensee HG, Jung G. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008; 68:1221-7; PMID:18281499; http://dx.doi.org/10.1158/0008-5472.CAN-07-6175
20. Carlring J, De Leenheer E, Heath AW. A novel redox method for rapid production of functional bispecific antibodies for use in early pilot studies. PLoS One 2011; 6:e22533; PMID:21811628; http://dx.doi.org/10.1371/journal.pone. 0022533
21. De Lau WB, Heije K, Neefjes JJ, Oosterwegel M, Rozemuller E, Bast BJ. Absence of preferential homologous H/L chain association in hybrid hybridomas. J Immunol 1991; 146:906-14; PMID:1899099
22. Ménard S, Canevari S, Colnaghi MI. Hybrid antibodies in cancer diagnosis and therapy. Int J Biol Markers 1989; 4:131-4; PMID:2693537
23. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994; 264:833-5; PMID:8171337; http://dx.doi.org/10.1126/science. 8171337
24. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155:219-25; PMID:7602098
25. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163:1246-52; PMID:10415020
26. Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010; 2:309-19; PMID:20418662; http://dx.doi.org/10.4161/mabs. 2.3.11791
27. Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065; http://dx.doi.org/10.1016/S0022-1759(00)00339-2
28. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
29. Zhu Z, Presta LG, Zapata G, Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997; 6:781-8; PMID:9098887; http://dx.doi.org/10.1002/pro.5560060404
30. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
31. Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26-35; PMID:9231898; http://dx.doi.org/10.1006/jmbi.1997.1116
32. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360-8; PMID:18519697; http://dx.doi.org/10.1158/0008-5472.CAN-07-5960
33. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12:6144-52; PMID:17062691; http://dx.doi.org/10. 1158/1078-0432.CCR-05-1418
34. Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011; 11:1655-62; PMID:22047509; http://dx.doi.org/10.1517/14712598.2011.626762
35. Igawa T, Tsunoda H. Methods for producing polypeptides by regulating polypeptide association. WO2006106905. 2006
36. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382. 22123055
37. Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 2011; 3:546-57.; PMID:22123055; http://dx.doi.org/10.4161/mabs.3.6.18123
38. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195-202; PMID:20299542; http://dx.doi.org/10.1093/protein/gzp094
39. Muda M, Gross AW, Dawson JP, He C, Kurosawa E, Schweickhardt R, et al. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng Des Sel 2011; 24:447-54; PMID:21498564; http://dx.doi.org/10.1093/protein/gzq123
40. Pack P, Kujau M, Schroeckh V, Knüpfer U, Wenderoth R, Riesenberg D, et al. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology (N Y) 1993; 11:1271-7; PMID:7764189
41. Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992; 148:1547-53; PMID:1531669
42. Christensen EH, Eaton DL, Vendel AC, Wranik B. Coiled coil and/or tether containing protein complexes and uses thereof. WO2011034605. 2011
43. Houtzager E, Pinto RD, Logtenberg T, Throsby M, Kramer RA, De Kruif CA. Antibody producing non-mammals. WO2009157771. 2009
44. McWhirter J, Macdonald L, Stevens S, Davis S, Buckler DR, Murphy AJ. Common light chain mouse. WO2011097603. 2011
45. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850-9; PMID:20444694; http://dx.doi.org/10.1074/jbc.M110.113910
46. Igawa T, Tsunoda H, Kikuchi Y, Yoshida M, Tanaka M, Koga A, et al. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist singlechain diabody. Protein Eng Des Sel 2010; 23:667-77; PMID:20576629; http://dx.doi.org/10.1093/protein/ gzq034
47. Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
48. Cain C. Crossing over to bispecificity. SciBX 2011; 4:1-4
49. Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, Bates DO. A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. Microcirculation 2011; 18:598-607; PMID:21851472; http://dx.doi.org/10.1111/j. 1549-8719.2011.00120.x
50. Davis S, Smith E, Macdonald D, Olson KL. Readily isolated bispecific antibodies with native immunoglobulin format. WO2010151792. 2011
51. Igawa T, Tsunoda H. Antibody Modification Method For Purifying Bispecific Antibody. WO2007114325. 2011
52. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011; 3:84ra44; PMID:21613623; http://dx.doi.org/10.1126/ scitranslmed.3002230
53. Stubenrauch K, Wessels U, Regula JT, Kettenberger H, Schleypen J, Kohnert U. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos 2010; 38:84-91; PMID:19850673; http://dx.doi.org/10.1124/dmd.109.029751
54. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt.1553
55. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554-7; PMID:17872445; http://dx.doi.org/10.1126/science.1144603
56. Labrijn AF, Meesters J, van den BremerE, Neijssen JJ, van Berkel P, de Goeij B, et al. Heterodimeric Antibody Fc-Containing Proteins And Methods For Production Thereof. WO2011131746. 2011
57. Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-19; PMID:22543237; http://dx.doi.org/10.1016/j.jmb.2012. 04.020
58. Fagète S, Fischer N. Smarter drugs: a focus on pan-specific monoclonal antibodies. BioDrugs 2011; 25:357-64; PMID:22050338; http://dx.doi.org/10.2165/11594690-000000000-00000
59. Buatois V, Fagète S, Magistrelli G, Chatel L, Fischer N, Kosco-Vilbois MH, et al. Pan-CC chemokine neutralization restricts splenocyte egress and reduces inflammation in a model of arthritis. J Immunol 2010; 185:2544-54; PMID:20644170; http://dx.doi.org/10.4049/jimmunol.1000182
60. Alejo A, Ruiz-Argüello MB, Ho Y, Smith VP, Saraiva M, Alcami A. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci U S A 2006; 103:5995-6000; PMID:16581912; http://dx.doi.org/10.1073/pnas.0510462103
61. Fagète S, Rousseau F, Magistrelli G, Gueneau F, Ravn U, Kosco-Vilbois MH, et al. Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry. J Biol Chem 2012; 287:1458-67; PMID:22041899; http://dx.doi.org/10.1074/jbc. M111.253658
62. Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One 2011; 6:e17887; PMID:21526167; http://dx.doi.org/10.1371/journal.pone.0017887
63. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610-4; PMID:19299620; http://dx.doi.org/10. 1126/science.1165480
64. Bostrom J, Lee CV, Haber L, Fuh G. Improving antibody binding affinity and specificity for therapeutic development. [xiii.]. Methods Mol Biol 2009; 525:353-76, xiii; PMID:19252851; http://dx.doi.org/10.1007/978-1-59745-554-1-19
65. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
66. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010; 23:289-97; PMID:20150180; http://dx.doi.org/10.1093/protein/gzq005
67. Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011; 17:1001-11; PMID:21233403; http://dx.doi.org/10.1158/1078-0432.CCR-10-2317